The First Participants in a Clinical Study of an HIV Experimental Vaccine Based on Moderna’s mRNA Technology Have Been Vaccinated

According to the announcement made by Moderna earlier this week, the first participants have been vaccinated in Phase 1 clinical trial of an experimental HIV vaccine that uses Moderna’s mRNA technology.

The trial, named IAVI G002, is being carried out in collaboration with IAVI, a nonprofit scientific research organization. It is examining a vaccine that provides HIV-definite antigens to the body to incite an immune response.

These antigens were previously developed by researchers at IAVI and Scripps Research, headed by Dr. William Schief.

Earlier this year, in a “proof-of-concept” trial, the research team discovered that HIV antigens developed the required immune response among 97 percent of participants.

Ricky Gervais Wants His New Stand-up Show, ‘Armageddon,’ to Be Cancelled

The current trial develops on the earlier one by testing the preliminary version of the vaccine and a booster version, as well and by incorporating Moderna’s mRNA technology, which was initially utilized to form a successful COVID-19 vaccine.

In a news release from Moderna, IAVI’s president and CEO, Mark Feinberg said “We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform.

The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine.”

First patients vaccinated
First patients vaccinated

A Trial Funded by the Bill & Melinda Gates Foundation, in Part

The new trial, financed partly by the Bill & Melinda Gates Foundation, will keep an eye on 56 HIV-negative adult participants, to review both the safety and efficiency of the vaccine.

48 of the volunteers will get at a minimum of one dose of the primary vaccine, thirty-two among which will also get the booster version as well. The rest of the eight will get the booster vaccine alone.

The trial has participants from 4 locations: Hope Clinic of Emory Vaccine Center, George Washington University School of Medicine, Fred Hutchinson Cancer Research Center, and the University of Texas Health Science Center at San Antonio.

Stimulus Update: IRS Announces All Third-Round Economic Impact Payments Have Been Sent

LEAVE A REPLY

Please enter your comment!
Please enter your name here